STOAF – A VENTURE FINANCE AND COMPETENCE HOUSE

STOAF (originally short for Stockholms Affärsänglar) has since its start in mid-2008 operated three angel funds. They have been focussed on B2B start-ups with strong technologies and global market potentials.

The financial market crises in 2008 limited the first fund´s capitalisation and recruitment of angels. In comparison with other microfunds of the same generation, Stoaf I delivered reasonable yields.

Investment areas of Stoaf III SciTech are B2Bs in

We offer co-investment rights

All our funds offer LPs the possibility to differentiate their portfolios´ upside potential via their co-investment rights. Thereby, their own portfolio composition including both direct and indirect investments in SciTech´s ventures may have a different upside and downside weight than the SciTech portfolio as such. This is achieved via their own preferences of investment areas or venture stages when they enter their direct investments. Thus, we offer investors the advantage of a professionally chosen early stage portfolio combined with their own narrower selection.

Research-based methodology

Our methodology is based on research into Best Market Practices in Silicon Valley, then further developed experimentally in Stoaf II cases. We take pride in having published two major methodological books, which openly present the methodological findings (by Stoaf co-founder and General Partner, Associate Prof. Lennart Ohlsson). The unique methodology aim at getting a better accuracy in predicting start-up developments as well as designing investment conditions aiming at achieving a successful reach of value inflection points. After financing, our methods in Venture Management and Exit Optimization is applied. These methods are interactively developed in our internal seminars by GPs and Certified Business Angels. All our competence partners are trained internally.

THE CASE: ALIGNED BIO

Focusing on two applications for their waveguiding nanowires: The next generation long-read DNA sequencing and high sensitivity biomarker sensors for disease detection and clinical research.

THE CASE: DEVELOPERATION

Developing a new operation method for treatment of hemorrhoids, making surgery possible without narcosis and with less postoperative pain.

THE CASE: LIMINA

The world’s first cloud-native Investment Management Solution for institutional investors.